Global Short Bowel Syndrome Market to Grow at a CAGR of Around 26% Through 2021, Reports Technavio

Technavio has published a new report on the global short bowel syndrome (SBS) market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--Technavio market research analysts forecast the global short bowel syndrome market to grow at a CAGR of close to 26% during the forecast period, according to their latest report.

The market study covers the present scenario and growth prospects of the global short bowel syndrome (SBS) market for 2017-2021. The report also GLP-2, growth hormone, and glutamine as the three major segments based on drug class, of which the GLP-2 segment accounted for 48% of the market share in 2016.

“The emerging markets have immense growth potential and present a huge opportunity for drug manufacturers to expand their businesses. The regulatory approval process for drugs is lenient in the emerging countries such as India, Bangladesh, and China. This allows for the easy entry of global and regional vendors in these markets,” says Sapna Jha, a lead analyst at Technavio for cardiovascular and metabolic disorders research.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio analysts highlight the following three market drivers that are contributing to the growth of the global SBS market:

  • Special drug designations
  • Increase in patient assistance programs
  • Shorter development timelines

Special drug designations

The R&D expenses are high for such novel molecules and hence, a special designation such as orphan drug status encourage the vendors to conduct such R&D, which otherwise would make the molecule economically unviable. Considering the patient pool for a rare disease is largely limited in most of the indications, the vendors find it difficult to recover the costs associated with the drug from discovery to launch status. However, the special designations such as fast track approval and orphan drug status provide the necessary stimulants to the drug makers, thereby, driving the market growth.

These designations carry benefits such as an extension of patent exclusivity period to address the need for an orphan drug, tax credits of up to 50% of R&D costs, and orphan drug’s sponsors are exempted from paying the US FDA application fees. These benefits will reduce the burden from vendors and encourage them to develop products for a rare disease.

Increase in patient assistance programs

Patient assistance programs by government and non-governmental organizations (NGOs) and major vendors propel the growth of the global SBS market.

“Individuals who cannot afford costly treatments are provided with financial assistance by state and federal agencies such as Social Security, Medicare, and Medicaid in the US,” says Sapna.

The Shire has introduced patient assistance program, OnePath, which aids with people who started treatment with GATTEX. This program will provide help to adults with SBS who are dependent on parenteral support. Since vendors also provide such programs, individuals show an inclination toward buying branded therapies, thereby increasing the market growth.

Shorter development timelines

The shorter development timelines are anticipated to have a positive impact on the market for orphan drugs during the forecast period. The clinical trials of orphan drugs are significantly shorter than those of non-orphan drugs owing to the special status. The average time required to launch an orphan drug from Phase II is 3.9 years, compared with 5.42 years for the non-orphan drugs. The clinical trials involving orphan diseases include fewer individuals than those for non-orphan diseases, which also adds to the shorter and faster development process. Also, orphan drugs not only present the benefit of shorter development timelines but also face comparatively fewer regulatory hurdles.

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like vaccines, urology devices, and oncology. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio market research analysts forecast the global short bowel syndrome market to grow at a CAGR of close to 26% during the forecast period, according to their latest report.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com